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mrc-epid.cam.ac.ukAbstractMany biomarkers are associated with type 2 diabetes (T2D) risk in epidemiological
observations. The aim of this study was to identify and summarize current evidence for
causal effects of biomarkers on T2D. A systematic literature search in PubMed and EMBASE
(until April 2015) was done to identify Mendelian randomization studies that examined
potential causal effects of biomarkers on T2D. To replicate the findings of identified studies,
data from two large-scale, genome-wide association studies (GWAS) were used: DIAbetes
Genetics Replication And Meta-analysis (DIAGRAMv3) for T2D and the Meta-Analyses of
Glucose and Insulin-related traits Consortium (MAGIC) for glycaemic traits. GWAS summary
statistics were extracted for the same genetic variants (or proxy variants), which were used in
the original Mendelian randomization studies. Of the 21 biomarkers (from 28 studies),
ten have been reported to be causally associated with T2D in Mendelian randomization.
Most biomarkers were investigated in a single cohort study or population. Of the ten
biomarkers that were identified, nominally significant associations with T2D or glycaemic
traits were reached for those genetic variants related to bilirubin, pro-B-type natriuretic
peptide, delta-6 desaturase and dimethylglycine based on the summary data from
DIAGRAMv3 or MAGIC. Several Mendelian randomization studies investigated the nature of
associations of biomarkers with T2D. However, there were only a few biomarkers that may
have causal effects on T2D. Further research is needed to broadly evaluate the causal effects
of multiple biomarkers on T2D and glycaemic traits using data from large-scale cohorts or






" type 2 diabetesicen
.0 UEndocrine Connections
(2015) 4, 249–260IntroductionOver the past decade, interest in studying biological
markers (biomarkers) for type2diabetes (T2D)has increased
intensely. This happened becausemultiple pathobiological
processes may contribute to the disease progression, which
provides an opportunity to introduce preventive and
therapeutic interventions for T2D (1). In clinical practice,
such biomarkers (e.g., glucose and glycated haemoglobintests) are widely used for the diagnosis of diabetes or for
themonitoring of therapeutic intervention (2, 3). Targeted
intervention at the biomarker level would be useful where
there is evidence for a causal relationship between an
exposure (like a biomarker) and T2D (4).
Traditional epidemiological studies lack sufficient


















Research A Abbasi Biomarkers and type 2 diabetes 2–12 4 :250confounding or reverse causality (4, 5, 6, 7). It has been
successfully shown that a complementary analysis of
genetic data, termed ‘Mendelian randomization,’ has
additive value to infer a causal association (4, 5, 6, 7, 8).
The main assumption for Mendelian randomization is
that the genetic variants do not change over time and are
inherited randomly (based on Mendel’s laws). In other
words, the genetic variants as proxy measures for
exposures (e.g., biomarkers) are essentially considered
free from confounding and reverse causation. Therefore,
the analysis of integrated observational-genetic data is
considered similar to that of the randomized trials (9, 10).
In Mendelian randomization, if there is a causal
association between a biomarker and T2D, the genetic
variant(s) influencing the biomarker and the outcome of
interest should be associated (5, 6, 8). In the current
study, evidence for causal associations between bio-
markers and the risk of T2D was updated via a systematic
literature search to identify Mendelian randomization
studies. Next, summary data from the two largest
genome-wide association studies (GWAS) for T2D or
glycaemic traits (10, 11) were used to examine the effect
estimates for each genetic variant compared with that of
the identified studies.Methods
Search strategy for candidate biomarkers
PubMed and EMBASE were searched to identify Mendelian
randomization studies examining the associations
between biomarkers and T2D until April 2015. The
overview of this systematic literature search was con-
ducted in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA)
guidelines, when applicable (12). A manual search was
also done for the references of included articles to identify
other relevant studies. Because a review of published
original studies was performed, the Declaration of Helsinki
items related to ‘approval of medical ethics committee’
and ‘permission acquisition’ are not applicable to the
current study.Selection criteria
Studies were included if they formally quantified a
causal association between one or more biomarkers
(as main exposures) and T2D (as the main outcome);
used data on biomarker-associated genetic variant; and
classified/defined the exposure as a biomarker that hashttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0087
 2015 The author
Published by Bioscientifica Ltd.been objectively measured in serum, plasma or urine.
The following MeSH keywords or related terms were
used: Diabetes mellitus, Type 2[Mesh], Type 2 Diabe-
tes[tiab], Diabetes[ti]; and Mendelian randomization,
Mendelian randomisation, instrumental variable,
genetic risk score or causal association.Data extraction and quality assessment
A primary plan was made to extract necessary data from
the full text of the original studies or to contact the
corresponding author(s) when appropriate. Fig. 1 depicts
the workflow of the literature search. T2D was determined
as the main outcome if one or more of the following
conditions were fulfilled: a physician diagnosed T2D as
indicated by a self-report or in a primary-care database;
fasting plasma glucose R7.0 mmol/l, a random sample
plasma glucoseR11.1 mmol/l; or the initiation of glucose-
lowering medication as retrieved from a pharmacy registry
or hospital records (11).Statistical analysis
All genetic variants that affect identified biomarkers were
obtained from the original Mendelian randomization
studies. To replicate the nature of the relationship
between each biomarker and the outcome (i.e., T2D or
glycaemic traits), a genetic approach using outcome-
association data for the biomarker-related genetic variants
was applied (5, 6, 8). In brief, to determine whether the
same genetic variants (or a suitable proxy variant) were
associated with T2D (or glycaemic traits), the correspond-
ing summary association statistics from GWAS for T2D
(DIAbetes Genetics Replication And Meta-analysis (DIA-
GRAMv3)) (13) and glycaemic traits (Meta-Analyses of
Glucose and Insulin-related traits Consortium (MAGIC))
(14) were extracted. DIAGRAMv3 is a meta-analysis of
multiple GWAS with a total number of 12 171 diabetes
cases and 56 862 controls of European descent (13).
Previously, details regarding the use of GWAS data for
Mendelian randomization were described (5, 6, 10, 11).
These selected single-test association analyses in the
GWAS data are equivalent to that of individual-level
data analysis (5, 6, 11).
Extracted data were tabulated on Excel spreadsheets.
All statistical analyses were conducted using Excel or
Stata/SE version 13.1 for Windows (http://cran.r-project.
org/). A two-sided P value !0.05 was considered nomin-
ally significant.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Literature search and study characteristics
After scanning 812 titles and selected abstracts, 33 articles
were selected for full text review (11, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36,
37, 38, 39, 40, 41, 42, 43, 44, 45, 46). The literature search
process is shown in Fig. 1. Five studies were excluded as
they did not measure a specific biomarker (nZ1) or
investigated a measure of insulin resistance as the main
exposure (nZ4). The characteristics of the 28 studies are
summarized in Table 1.The studies were performed in
different populations; most were cohort studies including
middle-aged adults in the USA or Europe and were
published between 2008 and 2015. Four studies were
conducted only in Asian populations including Chinese or
Taiwanese. In 12 studies, data from multiple GWAS were
combined to examine the associations between genotypeshttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0087
 2015 The author
Published by Bioscientifica Ltd.and T2D. Six of these studies used data from DIAGRAMv2
(nZ3) (47) or DIAGRAMv3 (nZ3) (13), and the other six
used at least two cohorts with genome-wide genotyping.
DIAGRAMv2 was a meta-analysis of eight GWAS compris-
ing 8130 individuals with T2D and 38 987 controls of
European descent (47). All Mendelian randomization
studies investigated only one biomarker as an exposure
in relation to T2D. Some studies also examined the causal
associations of a single biomarker with several other
outcomes such as cardiovascular disease (18, 24), rheuma-
toid arthritis (18) or osteoporosis (24). In the final sample,
studies included up to 28 144 T2D cases and 76 344 T2D
controls or total participants.Biomarkers and Mendelian randomization
From 28 studies, data were retrieved on causal associations
of biomarkers with T2D. In these studies, 21 uniqueThis work is licensed under a Creative Commons
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Published by Bioscientifica Ltd.biomarkers that were investigated at least once (16
biomarkers), twice (three biomarkers) and three times
(two biomarkers) were identified (Table 1); 19 biomarkers
were investigated in independent studies. However, the
two biomarkers with three Mendelian randomization
studies were investigated in combined studies where the
same sample, e.g., DIAGRAMv2 for adiponectin (19, 43),
or a part of whole cohort, e.g., European Prospective
Investigation into Cancer and Nutrition (EPIC)-Potsdam
for vitamin D (17, 45), were used to make total case-
s/controls. Eleven studies used one genetic variant as a
single instrumental variable in Mendelian randomization.
Eight studies used at least two independent genetic
variants in the same locus as instrumental variables. The
rest of the nine studies used multiple genetic variants in
different loci or created a multi-locus genetic risk score for
each biomarker.
In main or sensitivity analyses, four studies (11, 26,
44, 45) examined causal associations of bilirubin, lipopro-
tein (a), vitamin D, interleukin-1 receptor antagonist (with
corresponding biomarker-associated genotypes) with T2D
using the DIAGRAMv3 summary data. In Table 1, the
value for each causal estimate can be interpreted as odds
ratio (OR), hazard ratio (HR) or log OR (b coefficient) for
diabetes per one unit change in genetically determined
biomarkers or biomarker-associated genotypes. Evidence
of causal association was reported for adiponectin,
bilirubin, N-terminal pro B-type natriuretic peptide
(NT proBNP), delta-6 desaturase (D6D), dimethylglycine,
ferritin (transmembrane protease serine 6), homocysteine,
macrophage migration inhibitory factor (MIF), sex hor-
mone-binding protein (SHBG) and resistin (Table 1). For
adiponectin, causal estimates were calculated as an OR of
0.86 per allele (35) or a b coefficient of 0.3 for adiponectin
multi-locus genotypic risk score (19). Causal estimate for
bilirubin was reported as an OR of 0.58 per 1-S.D.
genetically increased log-transformed bilirubin (11). For
NT proBNP (37), D6D (30), dimethylglycine (32), ferritin
(22), MIF (23) and resistin (18), the expected ORs for
T2D were 0.96, 0.64, 1.1, 0.79, 1.74 and 1.38 per each copy
of risk alleles or genotypes, respectively. For homo-
cysteine, causal estimates were reported as an OR of
1.29/5 mmol/l genetically increased homocysteine (24) or
ORs of 1.93 and 1.52 for CC and CC/TT genotypes (25)
respectively. For SHBG, the expected ORs for T2D were
0.92 per each copy of the SHBG lowering allele (34) or
0.3/1-S.D. genetically increased natural log transformed
SHBG (21).
Using the GWAS data from DIAGRAMv3 or MAGIC
(13, 14), associations of the genetic variants influencingThis work is licensed under a Creative Commons
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tested. A nominally significance (P!0.05) was reached for
the genetic variants that affect bilirubin (PZ0.03 for
glucose and Homeostatic model assessment (HOMA)-
insulin resistance (IR)), NT proBNP (PZ0.03 for T2D),
D6D activity (PZ0.003 for T2D; PZ2.7!10K8 for glucose)
and dimethylglycine (PZ0.004 for glucose) in relation to
T2D or glycaemic traits (Table 2). For adiponectin, a
nominally significant association with T2D or glycaemic
traits was observed for seven out of 19 genetic variants.
All of these seven variants, except rs12637534, were
non-ADIPOQ adiponectin genetic variants. In line with
previous Mendelian randomization studies, the overall
effect of non-ADIPOQ variants on T2D or glycaemic traits
together with null association of ADIPOQ variants is
compatible with pleiotropic effects of adiponectin on
T2D (42).Discussion
This literature search of Mendelian randomization studies
shows here that ten out of 21 identified biomarkers were
reported to be causally associated with T2D. In particular,
the presence of potential causal associations (defined as
nominally significant) between the biomarker-related
variants and T2D and/or glycaemic traits can be confirmed
for four biomarkers using the publically available GWAS
data. The inconsistency between the identified studies and
the summary data from DIAGRAMv3 or MAGIC can be to
some extent explained by different design and populations
applying across studies, the possibility of false positive
associations, selection bias, the heterogeneity in T2D, the
use of varied sources to ascertain T2D cases, differences in
data quality control and pre-analysis preparations (6, 11).
Taken together, these findings support that the
oxidative stress system (bilirubin or metabolites of
bilirubin), the brain natriuretic peptide (BNP) hormone
system, D6D activity and dimethylglycine may contribute
to the development of diabetes or insulin resistance
through secondary effects (i.e., pleiotropy) or direct
mechanisms (11, 37, 42). Bilirubin that is the major end-
product of heme catabolism has antioxidant properties
and may compensate the oxidative stress (11, 48).
Oxidative stress has been shown as an important factor
in the pathophysiology of diabetes (11). At the cellular
level, bilirubin can be oxidized to its precursor, biliverdin,
to detoxify the excess of oxidants. Biliverdin is rapidly
recycled to bilirubin via the action of biliverdin reductase,
generating a physiologic cytoprotective cycle in several
tissues (49). The underlying mechanism of a protectivehttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0087
 2015 The author
Published by Bioscientifica Ltd.role of BNP in the aetiology of T2D is unknown in humans
(37). In mice, overexpressed BNP signalling cascade can
protect against diet-induced insulin resistance and obesity
through promoting muscle mitochondrial biogenesis and
fat oxidation (37, 50). The biological mechanisms of the
relationship between D6D activity and T2D are not well
understood (30). Although data of human experimental
studies are scarce, observational studies have shown that
D6D activity or lifestyle-induced changes in D6D activity
was associated with insulin resistance (30, 51, 52). Because
D6D catalyses the synthesis of fatty acids, one can
speculate that the link between D6D activity and T2D is
likely to bemediated by changes in fatty acid composition,
which in turn may affect insulin signalling and receptor-
binding affinities (30). Dimethylglycine is metabolized to
glycine by dimethylglycine dehydrogenase (DMGDH)
in mammals (32). Accordingly, a recent GWAS identified
that the DMGDH genetic variants were strongly associated
with blood-based dimethylglycine (53). Epidemiological
studies have observed an inverse association between the
precursor of dimethylglycine, betaine, and metabolic risk
factors (54) but a positive association of elevated glycine
with increased insulin sensitivity (32). In humans,
cardiometabolic effects of the inhibition of DMHDH or
the supplementation of dimethylglycine have not been
investigated (32). However, experimental animal studies
have suggested a protective role of dimethylglycine in
glucose metabolism through a reduction in DMGDH
function (32, 55, 56).
In the post-omics era, epidemiological studies basi-
cally suggest that the levels of a given biomarker differ
between patients with T2D (or the individuals at high risk
for developing diabetes) and individuals without diabetes
(2, 57). If the biomarker is not causally related to the
disease outcome, the process of developing diabetes may
cause the increase or decrease in the levels of the
biomarker, as one of the T2D consequences, called reverse
causality (4, 26, 37). Unmeasured confounding or
measured confounding factors with errors (for example,
physical activity by self-report) is another explanation for
the observed associations between most biomarkers and
T2D. In this context, the use of genetic data (as in
Mendelian randomization) can enhance the likelihood
that the association between a biomarker and T2D is
causal or not (4, 36, 37). The potential role of biomarkers
in the development of T2D and the trajectories of
glycaemic traits using longitudinal analysis remains to
be further confirmed (6, 11). The latter analytical
approach can provide insight into the potential value of
biomarkers, which indicates pathobiological signals ofThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.




Nominally significanceT2DM13 Glucose14 HOMA-IR14
Adiponectin rs1736653 – – – NA
rs2980879 0.96 0.96 0.93 Null
rs16861209 0.89 0.85 0.51 Null
rs601339 0.89 0.83 0.03 Yes
rs17300539 0.87 0.81 0.15 Null
rs7955516 0.86 0.84 0.83 Null
rs12922394 0.54 0.07 0.19 Null
rs3821799 0.51 0.19 0.80 Null
rs731839 0.41 0.34 0.01 Yes
rs3774261 0.32 0.44 0.76 Null
rs17366568 0.31 0.97 0.40 Null
rs7133378 0.16 0.21 0.33 Null
rs12637534 0.15 0.38 0.00 Yes
rs6810075 0.1 0.77 0.52 Null
rs998584 0.06 0.81 0.68 Null
rs1108842 0.032 0.47 0.05 Yes
rs3001032 0.029 0.27 0.00 Yes
rs1597466 0.009 0.06 0.47 Yes
rs2925979 0.002 0.05 0.18 Yes
Beta-carotene rs6564851 0.22 0.39 0.27 Null
Bilirubin rs6742078 0.1 0.02 0.03 Yes
NT proBNP rs198389 0.03 0.37 0.39 Yes
CRP rs1205 0.66 0.68 0.64 Null
rs3093077 0.048 0.95 0.39 Yes
rs1130864 – 0.12 0.77 Null
D6-desaturase rs174546 0.003 2.7!10K8 0.89 Yes
Dimethylglycine rs2431332 0.51 0.004 0.29 Yes
Ferritin/TMPRSS6 rs855791 1 0.09 0.25 Null
rs4820268 0.73 0.15 0.13 Null
Fetuin-a rs4917 0.08 0.11 0.67 Null
rs2248690 0.055 0.96 0.77 Null
Homocysteine rs4646356 0.88 0.43 0.35 Null
rs12134663 0.78 0.69 0.62 Null
rs1801131 0.22 0.61 0.24 Null
rs1801133 0.10 0.46 0.43 Null
IL-1Ra rs1542176 0.64 0.008 0.71 Yes
rs6743376 – 0.91 0.46 Null
LTL rs12880583 – – – NA
rs2228041 – – – NA
rs34368910 – – – NA
rs938886 0.88 0.042 0.74 Yes
rs4975605 0.66 0.45 0.61 Null
rs4888444 0.09 0.91 0.34 Null
Lp(a) rs10455872 0.36 0.42 0.32 Null
MIF rs1007888 0.39 0.22 0.94 Null
miRNAs rs12610873 0.033 0.80 0.71 Yes
rs531564 0.66 0.53 0.97 Null
rs2910164 0.52 0.01 0.36 Yes
Resistin rs3745367 0.77 0.99 0.58 Null
rs1423096 0.72 0.81 0.34 Null
SHBG rs12150660 0.18 0.52 0.24 Null
rs6259 0.94 0.42 0.35 Null
Triglycerides rs12285095 0.41 0.97 0.62 Null
rs7557067 0.9 0.78 0.15 Null
rs7679 0.88 0.90 0.29 Null
rs2954029 0.72 0.64 0.87 Null
rs662799 0.28 0.04 0.55 Yes
rs714052 0.28 0.81 0.80 Null
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Nominally significanceT2DM13 Glucose14 HOMA-IR14
rs7819412 0.08 0.80 0.01 Yes
rs328 0.03 0.05 0.04 Yes
rs17216525 0.00 0.98 0.81 Yes
Uric acid rs1165151 0.74 0.42 0.86 Null
rs2231142 0.73 0.83 0.36 Null
rs505802 0.62 0.60 0.62 Null
rs734553 0.57 0.20 0.72 Null
rs742132 0.25 0.50 0.91 Null
rs12356193 0.14 0.95 0.47 Null
rs12129861 0.08 0.94 0.50 Null
rs17300741 0.03 0.34 0.36 Yes
Vitamin-D rs10877012 – – – NA
rs3755967 0.74 0.85 0.19 Null
rs1155563 0.93 0.77 0.06 Null
rs2298850 0.66 0.89 0.15 Null
rs3829251 0.54 0.09 0.26 Null
rs3794060 0.34 0.28 0.10 Null
rs6599638 0.30 0.17 0.43 Null
rs10741657 0.23 0.37 0.08 Null
rs12785878 0.14 0.32 0.17 Null
rs17217119 0.06 0.36 0.21 Null
rs6013897 0.06 0.33 0.12 Null
Vitamin D-BP rs2282679 0.76 1.00 0.12 Null
*P values for each of the biomarker variants were extracted from publicly available meta-analyses of genome-wide association studies (13, 14). NA, not
applicable; CRP, C-reactive protein; BNP, brain natriuretic peptide; interleukin 1 receptor antagonist (IL1-Ra); Lp(a), Lipoprotein(a); LTL, leukocyte telomere
length; MIF, macrophage migration inhibitory factor; NT proBNP, N-terminal pro B-type natriuretic peptide; SHBG, sex hormone binding globulin, Vitamin
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influenced by the interactions of multiple genes or a
gene may have been mapped to multiple biomarkers
rather than the biomarker of interest (4, 13, 14). Thus, an
extensive knowledge of gene function and biological
processes and that the genome interacts with environ-
mental factors is needed to better understand how genetic
variations in the human genome contributes to lifelong
risk of T2D (4, 11, 13, 14, 57).
In this review, most studies only investigated a single
biomarker-diabetes association, and statistically signi-
ficant associations are reported more often. Here,
publication bias should be considered. Other limitations
include the lack of complementary analyses in the
genetic associations for glycaemic traits and that set of
genetic variants or large-scale GWAS for biomarkers were
scarce. Similarly, the Mendelian randomization approach
using GWAS summary statistics can be extended as a
secondary analysis of several datasets that have data on
the biomarker-associated variants (or their proxies) for
several diseases or traits. This multidisciplinary research
requires that a large group of consortia are contacted to
obtain summary association statistics from GWAShttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0087
 2015 The author
Published by Bioscientifica Ltd.consortia for outcomes of interest. Moreover, for the
biomarkers linked to T2D, underlying biological
mechanisms remain unknown. To uncover the under-
lying mechanisms, one needs to perform a comp-
lementary strand of experimental research. Before that,
an in silico functional gene network (pathway) analysis
can be used to speculate on the possible biological
mechanisms of biomarker-disease associations (58, 59).
Finally, Mendelian randomization cannot completely
control for the possibility of developmental compen-
sation, called canalization, confounding and pleiotropic
effects (5, 6, 8, 11, 37).
In conclusion, this is the first study that updates
evidence for causal associations between biomarkers and
T2D to date. Several Mendelian randomization studies
investigated the nature of associations of biomarkers with
T2D. Most biomarkers were investigated in a single cohort
study or population. However, there were only a few
biomarkers that may have causal effects on T2D. Further
research is warranted to broadly evaluate the causal effects
of multiple biomarkers on T2D and glycaemic traits using
data from large-scale cohorts or combined GWAS includ-
ing many different genetic variants. This genetic approachThis work is licensed under a Creative Commons

















Research A Abbasi Biomarkers and type 2 diabetes 10–12 4 :258may advance our understanding of the causes of T2D and
potentially enable us to explore novel targets for the
prevention and treatment of diabetes.Declaration of interest
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